Specificity of BCR-ABL antisense oligonucleotides.
Smetsers
T F
TF
Mensink
E J
EJ
D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology* / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*; D014176:Protein Biosynthesis / Q000187:drug effects; D016315:Proto-Oncogene Proteins c-abl / Q000096:biosynthesis / Q000235:genetics; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D016376:Oligonucleotides, Antisense; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl